{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:56:37Z","timestamp":1790553397244,"version":"4.1.0"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T00:00:00Z","timestamp":1527638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.neuint.2017.12.011","type":"journal-article","created":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T03:16:38Z","timestamp":1514862998000},"page":"84-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["A refined concept: \u03b1-synuclein dysregulation disease"],"prefix":"10.1016","volume":"119","author":[{"given":"Hideki","family":"Mochizuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Jing","family":"Choong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer","family":"Masliah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuint.2017.12.011_bib1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1212\/WNL.57.3.456","article-title":"Frequency of bowel movements and the future risk of Parkinson's disease","volume":"57","author":"Abbott","year":"2001","journal-title":"Neurology"},{"issue":"6148","key":"10.1016\/j.neuint.2017.12.011_bib2","doi-asserted-by":"crossref","first-page":"1233151","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome","volume":"341","author":"Aiuti","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.neuint.2017.12.011_bib3","doi-asserted-by":"crossref","first-page":"17625","DOI":"10.1038\/srep17625","article-title":"Synchrotron FTIR micro-spectroscopy for structural analysis of Lewy bodies in the brain of Parkinson's disease patients","volume":"5","author":"Araki","year":"2015","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.neuint.2017.12.011_bib4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1185\/030079902125000787","article-title":"Treatment with atorvastatin to the National Cholesterol Educational Program goal versus \u2018usual\u2019 care in secondary coronary heart disease prevention. The Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study","volume":"18","author":"Athyros","year":"2002","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.neuint.2017.12.011_bib5","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1074\/jbc.M412106200","article-title":"Mechanisms of Suppression of alpha-synuclein neurotoxicity by geldanamycin in Drosophila","volume":"280","author":"Auluck","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"issue":"39","key":"10.1016\/j.neuint.2017.12.011_bib6","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular \u03b1-synuclein prevents cell-to-cell aggregate transmission","volume":"32","author":"Bae","year":"2012","journal-title":"J.\u00a0Neurosci."},{"issue":"2","key":"10.1016\/j.neuint.2017.12.011_bib7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ana.21540","article-title":"Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy","volume":"65","author":"Banno","year":"2009","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.neuint.2017.12.011_bib8","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/j.1471-4159.2008.05254.x","article-title":"Statins reduce neuronal alpha-synuclein aggregation in in\u00a0vitro models of Parkinson's disease","volume":"105","author":"Bar-On","year":"2008","journal-title":"J.\u00a0Neurochem."},{"issue":"4","key":"10.1016\/j.neuint.2017.12.011_bib9","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1471-4159.2006.04017.x","article-title":"Effects of the cholesterol-lowering compound methyl-beta-cyclodextrin in models of alpha-synucleinopathy","volume":"98","author":"Bar-On","year":"2006","journal-title":"J.\u00a0Neurochem."},{"issue":"2","key":"10.1016\/j.neuint.2017.12.011_bib10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00401-008-0450-7","article-title":"Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders","volume":"117","author":"Beach","year":"2009","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuint.2017.12.011_bib11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0022-510X(73)90175-5","article-title":"Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations","volume":"20","author":"Bernheimer","year":"1973","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.neuint.2017.12.011_bib12","doi-asserted-by":"crossref","first-page":"34574","DOI":"10.1074\/jbc.M005514200","article-title":"Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs","volume":"275","author":"Biere","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"issue":"17","key":"10.1016\/j.neuint.2017.12.011_bib13","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.1073\/pnas.0910723107","article-title":"EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity","volume":"107","author":"Bieschke","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6148","key":"10.1016\/j.neuint.2017.12.011_bib14","doi-asserted-by":"crossref","first-page":"1233158","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.neuint.2017.12.011_bib15","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.sleep.2012.10.015","article-title":"Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder","volume":"14","author":"Boeve","year":"2013","journal-title":"Sleep Med."},{"key":"10.1016\/j.neuint.2017.12.011_bib16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.cell.2005.10.017","article-title":"Snaring the function of alpha-synuclein","volume":"123","author":"Bonini","year":"2005","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.neuint.2017.12.011_bib17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nchembio782","article-title":"Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization","volume":"2","author":"Bosco","year":"2006","journal-title":"Nat. Chem. Biol."},{"issue":"2","key":"10.1016\/j.neuint.2017.12.011_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"10.1016\/j.neuint.2017.12.011_bib19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jmb.2010.10.027","article-title":"The anti-Parkinsonian drug selegiline delays the nucleation phase of \u03b1-synuclein aggregation leading to the formation of nontoxic species","volume":"405","author":"Braga","year":"2011","journal-title":"J.\u00a0Mol. Biol."},{"issue":"9","key":"10.1016\/j.neuint.2017.12.011_bib20","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.peptides.2008.05.005","article-title":"Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein","volume":"29","author":"Brandt","year":"2008","journal-title":"Peptides"},{"issue":"9","key":"10.1016\/j.neuint.2017.12.011_bib21","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nrn2477","article-title":"Research in motion: the enigma of Parkinson's disease pathology spread","volume":"2008","author":"Brundin","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"issue":"5","key":"10.1016\/j.neuint.2017.12.011_bib22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/ana.21541","article-title":"A\u00a0critical evaluation of the Braak staging scheme for Parkinson's disease","volume":"64","author":"Burke","year":"2008","journal-title":"Ann. Neurol."},{"issue":"40","key":"10.1016\/j.neuint.2017.12.011_bib23","doi-asserted-by":"crossref","first-page":"E4274","DOI":"10.1073\/pnas.1416598111","article-title":"\u03b1-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation","volume":"111","author":"Burr\u00e9","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"issue":"5999","key":"10.1016\/j.neuint.2017.12.011_bib24","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1126\/science.1195227","article-title":"Alpha-synuclein promotes SNARE-complex assembly in\u00a0vivo and in\u00a0vitro","volume":"329","author":"Burr\u00e9","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.neuint.2017.12.011_bib25","doi-asserted-by":"crossref","first-page":"8797","DOI":"10.1523\/JNEUROSCI.22-20-08797.2002","article-title":"Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein","volume":"22","author":"Cabin","year":"2002","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuint.2017.12.011_bib26","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nchembio.283","article-title":"A\u00a0causative link between the structure of aberrant protein oligomers and their toxicity","volume":"6","author":"Campioni","year":"2010","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.neuint.2017.12.011_bib27","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1042\/BJ20111924","article-title":"Toxic prefibrillar \u03b1-synuclein amyloid oligomers adopt a distinctive antiparallel \u03b2-sheet structure","volume":"443","author":"Celej","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuint.2017.12.011_bib28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.brainres.2013.05.016","article-title":"RNA interference targeting \u03b1-synuclein attenuates methamphetamine-induced neurotoxicity in SH-SY5Y cells","volume":"1521","author":"Chen","year":"2013","journal-title":"Brain Res."},{"key":"10.1016\/j.neuint.2017.12.011_bib29","first-page":"3257","article-title":"Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation","volume":"119","author":"Chen","year":"2009","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuint.2017.12.011_bib30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0014-2999(00)00563-X","article-title":"Structure and function of the dopamine transporter","volume":"405","author":"Chen","year":"2000","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuint.2017.12.011_bib31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nbd.2006.08.021","article-title":"Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease?","volume":"25","author":"Chu","year":"2007","journal-title":"Neurobiol. Dis."},{"issue":"9435","key":"10.1016\/j.neuint.2017.12.011_bib32","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"9411","key":"10.1016\/j.neuint.2017.12.011_bib33","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(04)15690-0","article-title":"Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions","volume":"363","author":"Collins","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.neuint.2017.12.011_bib34","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/hmg\/ddr477","article-title":"Acevedo-Arozena A. \u03b1-Synuclein levels modulate Huntington's disease in mice","volume":"21","author":"Corrochano","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuint.2017.12.011_bib35","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cell.2012.03.037","article-title":"Direct observation of the interconversion of normal and toxic forms of \u03b1-synuclein","volume":"149","author":"Cremades","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.neuint.2017.12.011_bib36","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0014-5793(98)01146-6","article-title":"Synthetic filaments assembled from C-terminally truncated alpha-synuclein","volume":"436","author":"Crowther","year":"1998","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuint.2017.12.011_bib37","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1471-4159.2009.06324.x","article-title":"Seeding induced by \u03b1-synuclein oligomers provides evidence for spreading of \u03b1-synuclein pathology","volume":"111","author":"Danzer","year":"2009","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuint.2017.12.011_bib38","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/qjmed\/hcq142","article-title":"A\u00a0basic smell test is as sensitive as a dopamine transporter scan: comparison of olfaction, taste and DaTSCAN in the diagnosis of Parkinson's disease","volume":"103","author":"Deeb","year":"2010","journal-title":"Q.\u00a0J. Med"},{"key":"10.1016\/j.neuint.2017.12.011_bib39","doi-asserted-by":"crossref","first-page":"13010","DOI":"10.1073\/pnas.0903691106","article-title":"Inclusion formation and neuronal cell death through neuron-to-neuron transmission of \u03b1-synuclein","volume":"106","author":"Desplats","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1016\/j.neuint.2017.12.011_bib40","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0028-3908(03)00140-0","article-title":"Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease","volume":"45","author":"Dev","year":"2003","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.neuint.2017.12.011_bib41","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"Alzheimer's disease cooperative study steering committee, Siemers E, Sethuraman G, Mohs R; semagacestat study group. A phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"4","key":"10.1016\/j.neuint.2017.12.011_bib42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Alzheimer's disease cooperative study steering committee; solanezumab study group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuint.2017.12.011_bib43","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1136\/jnnp.55.2.138","article-title":"Bilateral olfactory dysfunction in early stage treated and untreated idiopathicParkinson's disease","volume":"55","author":"Doty","year":"1992","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.neuint.2017.12.011_bib44","doi-asserted-by":"crossref","first-page":"8870","DOI":"10.1021\/bi034028+","article-title":"A\u00a0peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha synuclein","volume":"42","author":"Du","year":"2003","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.neuint.2017.12.011_bib45","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nsmb.1437","article-title":"EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers","volume":"15","author":"Ehrnhoefer","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.neuint.2017.12.011_bib46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.nbd.2017.05.002","article-title":"Differential effects of immunotherapy with antibodies targeting \u03b1-synuclein oligomers and fibrils in a transgenic model of synucleinopathy","volume":"104","author":"El-Agnaf","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuint.2017.12.011_bib47","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1006\/jsbi.2000.4262","article-title":"Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins","volume":"130","author":"El-Agnaf","year":"2000","journal-title":"J.\u00a0Struct. Biol."},{"key":"10.1016\/j.neuint.2017.12.011_bib48","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1006\/jmbi.2001.4538","article-title":"Conformational properties of alpha-synuclein in its free and lipid-associated states","volume":"307","author":"Eliezer","year":"2001","journal-title":"J.\u00a0Mol. Biol."},{"issue":"2","key":"10.1016\/j.neuint.2017.12.011_bib49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejcb.2017.01.002","article-title":"Impact of high cholesterol in a Parkinson's disease model: prevention of lysosomal leakage versus stimulation of \u03b1-synuclein aggregation","volume":"96","author":"Eriksson","year":"2017","journal-title":"Eur. J. Cell Biol."},{"issue":"10","key":"10.1016\/j.neuint.2017.12.011_bib50","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/acn3.338","article-title":"Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies","volume":"3","author":"Fairfoul","year":"2016","journal-title":"Ann. Clin. Transl. Neurol"},{"key":"10.1016\/j.neuint.2017.12.011_bib51","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncb748","article-title":"Alpha-synuclein is phosphorylated in synucleinopathy lesions","volume":"4","author":"Fujiwara","year":"2002","journal-title":"Nat. Cell Biol."},{"issue":"3","key":"10.1016\/j.neuint.2017.12.011_bib52","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ajpath.2012.11.018","article-title":"Axonopathy in an \u03b1-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated \u03b1-synuclein","volume":"182","author":"Games","year":"2013","journal-title":"Am. J. Pathol."},{"issue":"28","key":"10.1016\/j.neuint.2017.12.011_bib53","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models","volume":"34","author":"Games","year":"2014","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuint.2017.12.011_bib54","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0896-6273(95)90040-3","article-title":"Characterization of a novel protein regulated during the critical period for song learning in the zebra finch","volume":"15","author":"George","year":"1995","journal-title":"Neuron"},{"issue":"7","key":"10.1016\/j.neuint.2017.12.011_bib55","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1523\/JNEUROSCI.5983-09.2010","article-title":"Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology","volume":"30","author":"Gerard","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuint.2017.12.011_bib56","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.290.5493.985","article-title":"Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions","volume":"290","author":"Giasson","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.neuint.2017.12.011_bib57","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1073\/pnas.94.3.769","article-title":"SNAREs and regulated vesicle exocytosis","volume":"94","author":"Goda","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"issue":"8","key":"10.1016\/j.neuint.2017.12.011_bib58","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/mt.2010.115","article-title":"In\u00a0vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration","volume":"18","author":"Gorbatyuk","year":"2010","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.neuint.2017.12.011_bib59","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cell.2013.05.057","article-title":"Distinct \u03b1-synuclein strains differentially promote tau inclusions in neurons","volume":"154","author":"Guo","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.neuint.2017.12.011_bib60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.brainres.2011.02.041","article-title":"A\u00a0microRNA embedded AAV \u03b1-synuclein gene silencing vector for dopaminergic neurons","volume":"1386","author":"Han","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.neuint.2017.12.011_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp.62.5.436","article-title":"Olfactory dysfunction inParkinson's disease","volume":"62","author":"Hawkes","year":"1997","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatr."},{"issue":"12","key":"10.1016\/j.neuint.2017.12.011_bib62","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/jnnp-2017-316015","article-title":"Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy: natural history-controlled study","volume":"88","author":"Hashizume","year":"2017","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.neuint.2017.12.011_bib63","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.bbrc.2006.01.057","article-title":"Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model","volume":"25","author":"Hayashita-Kinoh","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.neuint.2017.12.011_bib64","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00401-013-1214-6","article-title":"Accumulation of \u03b1-synuclein in the bowel of patients in the pre-clinical phase of Parkinson's disease","volume":"127","author":"Hilton","year":"2014","journal-title":"Acta Neuropathol."},{"issue":"2","key":"10.1016\/j.neuint.2017.12.011_bib65","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.expneurol.2009.03.003","article-title":"Anti-aggregation and fibril-destabilizing effects of sex hormones on alpha-synuclein fibrils in\u00a0vitro","volume":"217","author":"Hirohata","year":"2009","journal-title":"Exp. Neurol."},{"issue":"3","key":"10.1016\/j.neuint.2017.12.011_bib66","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.neuropharm.2007.11.010","article-title":"Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in\u00a0vitro","volume":"54","author":"Hirohata","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuint.2017.12.011_bib67","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2017.12.011_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.neuint.2017.12.011_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.febslet.2011.01.009","article-title":"The role of the C-terminus of human \u03b1-synuclein: intra-disulfide bonds between the C-terminus and other regions stabilize non-fibrillar monomeric isomers","volume":"585","author":"Hong","year":"2011","journal-title":"FEBS Lett."},{"issue":"10","key":"10.1016\/j.neuint.2017.12.011_bib70","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.bbadis.2016.07.008","article-title":"Baicalein inhibits \u03b1-synuclein oligomer formation and prevents progression of \u03b1-synuclein accumulation in a rotenone mouse model of Parkinson's disease","volume":"1862","author":"Hu","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"10.1016\/j.neuint.2017.12.011_bib71","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bbrc.2015.12.043","article-title":"\u03b1-Synuclein aggregation, seeding and inhibition by scyllo-inositol","volume":"469","author":"Ibrahim","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.neuint.2017.12.011_bib72","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/mds.23001","article-title":"Cardiac sympathetic degeneration correlates with olfactory function in Parkinson's disease","volume":"25","author":"Iijima","year":"2010","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.neuint.2017.12.011_bib73","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1586\/eci.11.93","article-title":"Solanezumab for the treatment of mild-to-moderate Alzheimer's disease","volume":"8","author":"Imbimbo","year":"2012","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.neuint.2017.12.011_bib74","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1474-4422(10)70216-7","article-title":"Decreased striatal dopamine transporters uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study","volume":"9","author":"Iranzo","year":"2010","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.neuint.2017.12.011_bib75","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0896-6273(95)90302-X","article-title":"The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system","volume":"14","author":"Iwai","year":"1995","journal-title":"Neuron"},{"issue":"7","key":"10.1016\/j.neuint.2017.12.011_bib76","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.bbadis.2008.07.006","article-title":"A\u00a0critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders","volume":"1792","author":"Jellinger","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"issue":"12","key":"10.1016\/j.neuint.2017.12.011_bib77","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1021\/acschemneuro.7b00261","article-title":"Comparison of \u03b1-synuclein fibril inhibition by four different amyloid inhibitors","volume":"8","author":"Jha","year":"2017","journal-title":"ACS Chem Neurosci"},{"issue":"8","key":"10.1016\/j.neuint.2017.12.011_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006563","article-title":"Cross-seeding of prions by aggregated \u03b1-synuclein leads to transmissible spongiform encephalopathy","volume":"13","author":"Katorcha","year":"2017","journal-title":"PLoS Pathog."},{"issue":"9","key":"10.1016\/j.neuint.2017.12.011_bib79","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S1474-4422(10)70182-4","article-title":"Japan SBMA Interventional Trial for TAP-144-SR (JASMITT) study group. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"9","author":"Katsuno","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuint.2017.12.011_bib80","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brainres.2014.01.010","article-title":"Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects","volume":"1550","author":"Khodr","year":"2014","journal-title":"Brain Res."},{"key":"10.1016\/j.neuint.2017.12.011_bib81","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.brainres.2011.04.036","article-title":"An \u03b1-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons","volume":"1395","author":"Khodr","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.neuint.2017.12.011_bib82","doi-asserted-by":"crossref","first-page":"13782","DOI":"10.1021\/bi026284c","article-title":"Structural and functional implications of C terminal regions of alpha-synuclein","volume":"41","author":"Kim","year":"2002","journal-title":"Biochemistry"},{"issue":"24","key":"10.1016\/j.neuint.2017.12.011_bib83","doi-asserted-by":"crossref","first-page":"25497","DOI":"10.1074\/jbc.M400255200","article-title":"Hsp70 reduces alpha-synuclein aggregation and toxicity","volume":"279","author":"Klucken","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"issue":"2","key":"10.1016\/j.neuint.2017.12.011_bib84","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.expneurol.2009.11.015","article-title":"Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies","volume":"221","author":"Koob","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuint.2017.12.011_bib85","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nm1747","article-title":"Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease","volume":"14","author":"Kordower","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuint.2017.12.011_bib86","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1002\/mds.22369","article-title":"Transplanted dopaminergic neurons develop PD pathologic changes: a second case report","volume":"23","author":"Kordower","year":"2008","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.neuint.2017.12.011_bib87","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jprot.2010.11.010","article-title":"Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics","volume":"74","author":"Kroksveen","year":"2011","journal-title":"J.\u00a0Proteomics"},{"issue":"5","key":"10.1016\/j.neuint.2017.12.011_bib88","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0022-2836(02)00735-0","article-title":"Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils","volume":"322","author":"Lashuel","year":"2002","journal-title":"J.\u00a0Mol. Biol."},{"issue":"9","key":"10.1016\/j.neuint.2017.12.011_bib89","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.biocel.2008.01.017","article-title":"Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein","volume":"40","author":"Lee","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"2","key":"10.1016\/j.neuint.2017.12.011_bib90","article-title":"\u03b1-synuclein in Parkinson's disease","volume":"2","author":"Leonidas","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.neuint.2017.12.011_bib91","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nm1746","article-title":"Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation","volume":"14","author":"Li","year":"2008","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.neuint.2017.12.011_bib92","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/mds.23012","article-title":"Characterization of Lewy body pathology in 12- and 16-year old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease","volume":"25","author":"Li","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2017.12.011_bib93","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1073\/pnas.0406976102","article-title":"Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations","volume":"102","author":"Li","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"issue":"3","key":"10.1016\/j.neuint.2017.12.011_bib94","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1532-5415.2004.52109.x","article-title":"A\u00a0randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease","volume":"52","author":"Loeb","year":"2004","journal-title":"J.\u00a0Am. Geriatr. Soc."},{"issue":"10","key":"10.1016\/j.neuint.2017.12.011_bib95","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1021\/ja411577t","article-title":"The role of stable \u03b1-synuclein oligomers in the molecular events underlying amyloid formation","volume":"136","author":"Lorenzen","year":"2014","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.neuint.2017.12.011_bib96","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/hmg\/11.20.2395","article-title":"Impaired dopamine storage resulting from alpha synuclein mutations may contribute to the pathogenesis of Parkinson's disease","volume":"11","author":"Lotharius","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuint.2017.12.011_bib97","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molbrainres.2004.09.001","article-title":"Pathogenic effects of alpha-synuclein aggregation","volume":"134","author":"Lundvig","year":"2005","journal-title":"Mol. Brain Res."},{"issue":"2","key":"10.1016\/j.neuint.2017.12.011_bib98","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ane.12247","article-title":"Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review","volume":"130","author":"Malek","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.neuint.2017.12.011_bib99","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-015-0008-9","article-title":"Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy","volume":"10","author":"Mandler","year":"2015","journal-title":"Mol. Neurodegener."},{"issue":"6","key":"10.1016\/j.neuint.2017.12.011_bib100","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathol."},{"issue":"6","key":"10.1016\/j.neuint.2017.12.011_bib101","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.neuint.2017.12.011_bib102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLos One"},{"key":"10.1016\/j.neuint.2017.12.011_bib103","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.bbrc.2004.07.021","article-title":"Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in\u00a0vitro","volume":"321","author":"McLean","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.neuint.2017.12.011_bib104","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/mds.22510","article-title":"Neurochemical biomarkers in the differential diagnosis of movement disorders","volume":"24","author":"Mollenhauer","year":"2009","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.neuint.2017.12.011_bib105","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/gps.3846","article-title":"A\u00a0multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial","volume":"28","author":"Molloy","year":"2013","journal-title":"Int. J. Geriatr. Psychiatr."},{"issue":"9","key":"10.1016\/j.neuint.2017.12.011_bib106","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1523\/JNEUROSCI.20-09-03214.2000","article-title":"Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons","volume":"20","author":"Murphy","year":"2000","journal-title":"J.\u00a0Neurosci."},{"issue":"3","key":"10.1016\/j.neuint.2017.12.011_bib107","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1476-5381.2012.01846.x","article-title":"A\u00a0prolyl oligopeptidase inhibitor, KYP-2047, reduces \u03b1-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease","volume":"166","author":"My\u00f6h\u00e4nen","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"48","key":"10.1016\/j.neuint.2017.12.011_bib108","doi-asserted-by":"crossref","first-page":"17186","DOI":"10.1523\/JNEUROSCI.2220-12.2012","article-title":"Accumulation of \u03b1-synuclein triggered by presynaptic dysfunction","volume":"32","author":"Nakata","year":"2012","journal-title":"J.\u00a0Neurosci."},{"issue":"2","key":"10.1016\/j.neuint.2017.12.011_bib109","doi-asserted-by":"crossref","first-page":"344","DOI":"10.7150\/thno.16562","article-title":"Inhibition by multifunctional magnetic nanoparticles loaded with alpha-synuclein RNAi plasmid in a Parkinson's disease model","volume":"7","author":"Niu","year":"2017","journal-title":"Theranostics"},{"issue":"12","key":"10.1016\/j.neuint.2017.12.011_bib110","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1007\/s11064-017-2382-x","article-title":"The oligomer hypothesis in \u03b1-synucleinopathy","volume":"42","author":"Ono","year":"2017","journal-title":"Neurochem. Res."},{"issue":"2","key":"10.1016\/j.neuint.2017.12.011_bib111","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.expneurol.2007.03.002","article-title":"Anti-fibrillogenic and fibril-destabilizing activity of nicotine in\u00a0vitro: implications for the prevention and therapeutics of Lewy body diseases","volume":"205","author":"Ono","year":"2007","journal-title":"Exp. Neurol."},{"issue":"7","key":"10.1016\/j.neuint.2017.12.011_bib112","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/jnr.21271","article-title":"Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in\u00a0vitro","volume":"85","author":"Ono","year":"2007","journal-title":"J.\u00a0Neurosci. Res."},{"issue":"9","key":"10.1016\/j.neuint.2017.12.011_bib113","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.neurobiolaging.2011.10.015","article-title":"Effect of melatonin on \u03b1-synuclein self-assembly and cytotoxicity","volume":"33","author":"Ono","year":"2012","journal-title":"Neurobiol. Aging"},{"issue":"5","key":"10.1016\/j.neuint.2017.12.011_bib114","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1471-4159.2012.07847.x","article-title":"Cross-seeding effects of amyloid \u03b2-protein and \u03b1-synuclein","volume":"122","author":"Ono","year":"2012","journal-title":"J.\u00a0Neurochem."},{"issue":"1","key":"10.1016\/j.neuint.2017.12.011_bib115","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1471-4159.2006.03707.x","article-title":"Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in\u00a0vitro","volume":"97","author":"Ono","year":"2006","journal-title":"J.\u00a0Neurochem."},{"issue":"2","key":"10.1016\/j.neuint.2017.12.011_bib116","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.nbd.2006.10.010","article-title":"Vitamin A potently destabilizes preformed alpha-synuclein fibrils in\u00a0vitro: implications for Lewy body diseases","volume":"25","author":"Ono","year":"2007","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.neuint.2017.12.011_bib117","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1750-3639.2006.00032.x","article-title":"Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease","volume":"17","author":"Orimo","year":"2007","journal-title":"Brain Pathol."},{"issue":"Pt 3","key":"10.1016\/j.neuint.2017.12.011_bib118","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/brain\/awm302","article-title":"Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease","volume":"131","author":"Orimo","year":"2008","journal-title":"Brain"},{"issue":"Pt 4","key":"10.1016\/j.neuint.2017.12.011_bib119","first-page":"1093","article-title":"Detection of elevated levels of soluble \u03b1-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies","volume":"132","author":"Paleologou","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.neuint.2017.12.011_bib120","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1523\/JNEUROSCI.5922-09.2010","article-title":"Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions","volume":"30","author":"Paleologou","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuint.2017.12.011_bib121","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1471-4159.2004.02423.x","article-title":"Could a loss of \u03b1-synuclein function put dopaminergic neurons at risk?","volume":"89","author":"Perez","year":"2004","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuint.2017.12.011_bib122","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1523\/JNEUROSCI.22-08-03090.2002","article-title":"A\u00a0role for \u03b1-synuclein in the regulation of dopamine biosynthesis","volume":"22","author":"Perez","year":"2002","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuint.2017.12.011_bib123","doi-asserted-by":"crossref","first-page":"34393","DOI":"10.1074\/jbc.M004851200","article-title":"Interaction of human alpha-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis","volume":"275","author":"Perrin","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuint.2017.12.011_bib124","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1073\/pnas.042681599","article-title":"Aggregation of proteins with expanded glutamine and alanine repeats of the glutamine-rich and asparagine-rich domains of Sup35 and of the amyloid beta-peptide of amyloid plaques","volume":"99","author":"Perutz","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1016\/j.neuint.2017.12.011_bib125","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1016\/j.bpj.2012.04.050","article-title":"Fibrillar \u03b1-synuclein and huntingtin exon 1 assemblies are toxic to the cells","volume":"102","author":"Pieri","year":"2012","journal-title":"Biophys. J."},{"issue":"7","key":"10.1016\/j.neuint.2017.12.011_bib126","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1093\/hmg\/ddu606","article-title":"\u03b1-Synuclein modifies mutant huntingtin aggregation and neurotoxicity in Drosophila","volume":"24","author":"Po\u00e7as","year":"2015","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.neuint.2017.12.011_bib127","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1124\/jpet.109.158436","article-title":"Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity","volume":"332","author":"Putcha","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuint.2017.12.011_bib128","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.abb.2017.09.015","article-title":"The inhibitory effects of biomimetically designed peptides on \u03b1-synuclein aggregation","volume":"634","author":"Rezaeian","year":"2017","journal-title":"Arch. Biochem. Biophys."},{"issue":"5","key":"10.1016\/j.neuint.2017.12.011_bib129","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/alzrt146","article-title":"Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study","volume":"4","author":"Ringman","year":"2012","journal-title":"Alzheimer's Res. Ther."},{"issue":"Pt 5","key":"10.1016\/j.neuint.2017.12.011_bib130","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/brain\/awu057","article-title":"Accumulation of oligomer-prone \u03b1-synuclein exacerbates synaptic and neuronal degeneration in\u00a0vivo","volume":"137","author":"Rockenstein","year":"2014","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.neuint.2017.12.011_bib131","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/1753944708093847","article-title":"Stroke prevention: modifying risk factors","volume":"2","author":"Romero","year":"2008","journal-title":"Ther. Adv. Cardiovasc. Dis"},{"issue":"7","key":"10.1016\/j.neuint.2017.12.011_bib132","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/NEN.0b013e31829768d2","article-title":"\u03b1-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model","volume":"72","author":"Sanchez-Guajardo","year":"2013","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuint.2017.12.011_bib133","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/mds.23046","article-title":"Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization","volume":"25","author":"Saunders-Pullman","year":"2010","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.neuint.2017.12.011_bib134","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1212\/WNL.46.2.388","article-title":"Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder","volume":"46","author":"Schenck","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2017.12.011_bib135","first-page":"A316","article-title":"REM behavior disorder (RBD):delayed emergence of parkinsonism and\/or dementia in 65% of older men initially diagnosed with idiopathic RBD, and an analysis of the minimum and maximum tonic and\/or phasic electromyographicabnormalities found during REM sleep","volume":"26","author":"Schenck","year":"2003","journal-title":"Sleep"},{"issue":"12","key":"10.1016\/j.neuint.2017.12.011_bib136","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1074\/mcp.R113.032730","article-title":"Alpha-synuclein posttranslational modifications as potential biomarkers for Parkinson's disease and other synucleinopathies","volume":"12","author":"Schmid","year":"2013","journal-title":"Mol. Cell. Proteomics"},{"issue":"11","key":"10.1016\/j.neuint.2017.12.011_bib137","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1097\/NEN.0b013e31818b4126","article-title":"Region incidence and extent of Lewy body-related \u03b1-synucleinopathy in aging human olfactory bulb","volume":"67","author":"Sengoku","year":"2008","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuint.2017.12.011_bib138","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1073\/pnas.97.9.4897","article-title":"Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid- like cross-beta conformation","volume":"97","author":"Serpell","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"issue":"10043","key":"10.1016\/j.neuint.2017.12.011_bib139","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"issue":"9364","key":"10.1016\/j.neuint.2017.12.011_bib140","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.neuint.2017.12.011_bib141","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116841","article-title":"Anti-human \u03b1-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-\u03b1-synuclein rat model of Parkinson's disease","volume":"10","author":"Shahaduzzaman","year":"2015","journal-title":"PLos One"},{"issue":"6","key":"10.1016\/j.neuint.2017.12.011_bib142","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/mds.23838","article-title":"Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease","volume":"27","author":"Shannon","year":"2012","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.neuint.2017.12.011_bib143","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuint.2013.06.005","article-title":"Biomarkers in Parkinson's disease (recent update)","volume":"63","author":"Sharma","year":"2013","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuint.2017.12.011_bib144","doi-asserted-by":"crossref","first-page":"9110","DOI":"10.1073\/pnas.171300598","article-title":"Alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins","volume":"98","author":"Sharon","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"issue":"8","key":"10.1016\/j.neuint.2017.12.011_bib145","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1474-4422(11)70130-2","article-title":"CSF \u03b1-synuclein, tau, and amyloid \u03b2 in Parkinson's disease","volume":"10","author":"Shi","year":"2011","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.neuint.2017.12.011_bib147","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1212\/01.WNL.0000161874.52302.5D","article-title":"[99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease","volume":"64","author":"Siderowf","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2017.12.011_bib148","first-page":"1","article-title":"Alpha-synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease","volume":"565","author":"Sidhu","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuint.2017.12.011_bib149","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1096\/fj.03-1112rev","article-title":"Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?","volume":"18","author":"Sidhu","year":"2004","journal-title":"Faseb. J."},{"issue":"2","key":"10.1016\/j.neuint.2017.12.011_bib150","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jalz.2015.06.1893","article-title":"Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients","volume":"12","author":"Siemers","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neuint.2017.12.011_bib151","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1002\/mds.23325","article-title":"Olfactory heterogeneity in LRRK2 related Parkinsonism","volume":"25","author":"Silveira-Moriyama","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2017.12.011_bib152","doi-asserted-by":"crossref","first-page":"18344","DOI":"10.1074\/jbc.M000206200","article-title":"Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies","volume":"275","author":"Souza","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuint.2017.12.011_bib153","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0014-5793(00)01563-5","article-title":"Chaperone-like activity of synucleins","volume":"474","author":"Souza","year":"2000","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuint.2017.12.011_bib154","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.neuint.2017.12.011_bib155","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hipo.10006","article-title":"Age-dependent differential regulation of genes encoding APP and alpha-synuclein in hippocampal synaptic plasticity","volume":"12","author":"Stephan","year":"2002","journal-title":"Hippocampus"},{"issue":"49","key":"10.1016\/j.neuint.2017.12.011_bib156","doi-asserted-by":"crossref","first-page":"12485","DOI":"10.1523\/JNEUROSCI.2309-16.2016","article-title":"Inhibition of prolyl oligopeptidase restores spontaneous motor behavior in the \u03b1-synuclein virus vector-based Parkinson's disease mouse model by decreasing \u03b1-synuclein oligomeric species in mouse brain","volume":"36","author":"Svarcbahs","year":"2016","journal-title":"J.\u00a0Neurosci."},{"issue":"5","key":"10.1016\/j.neuint.2017.12.011_bib157","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/jnc.13180","article-title":"Phenolic compounds prevent the oligomerization of \u03b1-synuclein and reduce synaptic toxicity","volume":"134","author":"Takahashi","year":"2015","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuint.2017.12.011_bib158","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40478-016-0310-y","article-title":"Fasudil attenuates aggregation of \u03b1-synuclein in models of Parkinson's disease","volume":"4","author":"Tatenhorst","year":"2016","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"10.1016\/j.neuint.2017.12.011_bib159","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1474-4422(16)30395-7","article-title":"Solanezumab: too late in mild Alzheimer's disease?","volume":"16","author":"The Lancet Neurology","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuint.2017.12.011_bib160","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","article-title":"Detection of elevated levels of \u03b1-synuclein oligomers in CSF from patients with Parkinson disease","volume":"75","author":"Tokuda","year":"2010","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.neuint.2017.12.011_bib161","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/hmg\/ddr507","article-title":"\u03b1-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease","volume":"21","author":"Tom\u00e1s-Zapico","year":"2012","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.neuint.2017.12.011_bib162","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.celrep.2014.05.033","article-title":"\u0391-synuclein immunotherapy blocks uptake and templated propagation of misfolded \u03b1-synuclein and neurodegeneration","volume":"7","author":"Tran","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.neuint.2017.12.011_bib163","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1073\/pnas.90.23.11282","article-title":"Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease","volume":"90","author":"Ueda","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"issue":"9131","key":"10.1016\/j.neuint.2017.12.011_bib164","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"UKPDS-Group-Investigators Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"issue":"Pt 5","key":"10.1016\/j.neuint.2017.12.011_bib165","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/brain\/aww042","article-title":"Rifampicin is a candidate preventive medicine against amyloid-\u03b2 and tau oligomers","volume":"139","author":"Umeda","year":"2016","journal-title":"Brain"},{"issue":"39","key":"10.1016\/j.neuint.2017.12.011_bib166","doi-asserted-by":"crossref","first-page":"20811","DOI":"10.1074\/jbc.M116.744029","article-title":"FTY720\/Fingolimod reduces synucleinopathy and improves gut motility in A53T mice: contributions of pro-brain-derived neurotrophic factor (PRO-BDNF) and mature BDNF","volume":"291","author":"Vidal-Mart\u00ednez","year":"2016","journal-title":"J.\u00a0Biol. Chem."},{"issue":"19","key":"10.1016\/j.neuint.2017.12.011_bib167","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.cub.2014.08.027","article-title":"\u03b1-synuclein multimers cluster synaptic vesicles and attenuate recycling","volume":"24","author":"Wang","year":"2014","journal-title":"Curr. Biol."},{"issue":"21","key":"10.1016\/j.neuint.2017.12.011_bib168","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1523\/JNEUROSCI.0297-11.2011","article-title":"Induction of intracellular tau aggregation is promoted by \u03b1-synuclein seeds and provides novel insights into the hyperphosphorylation of tau","volume":"31","author":"Waxman","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuint.2017.12.011_bib169","doi-asserted-by":"crossref","first-page":"13709","DOI":"10.1021\/bi961799n","article-title":"NACP, a protein implicated in Alzheimer s disease and learning, is natively unfolded","volume":"35","author":"Weinreb","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuint.2017.12.011_bib170","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1096\/fj.03-0152fje","article-title":"Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress","volume":"17","author":"Wersinger","year":"2003","journal-title":"Faseb. J."},{"issue":"10","key":"10.1016\/j.neuint.2017.12.011_bib171","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1100976108","article-title":"In\u00a0vivo demonstration that alpha-synuclein oligomers are toxic","volume":"108","author":"Winner","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neuint.2017.12.011_bib172","doi-asserted-by":"crossref","first-page":"19509","DOI":"10.1074\/jbc.274.28.19509","article-title":"Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease","volume":"274","author":"Wood","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuint.2017.12.011_bib173","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nm0602-600","article-title":"Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease","volume":"8","author":"Xu","year":"2002","journal-title":"Nat. Med."},{"issue":"26","key":"10.1016\/j.neuint.2017.12.011_bib174","doi-asserted-by":"crossref","first-page":"26846","DOI":"10.1074\/jbc.M403129200","article-title":"The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils","volume":"279","author":"Zhu","year":"2004","journal-title":"J.\u00a0Biol. Chem."}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018617305715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018617305715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:45:40Z","timestamp":1759311940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018617305715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":173,"alternative-id":["S0197018617305715"],"URL":"https:\/\/doi.org\/10.1016\/j.neuint.2017.12.011","relation":{},"ISSN":["0197-0186"],"issn-type":[{"value":"0197-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A refined concept: \u03b1-synuclein dysregulation disease","name":"articletitle","label":"Article Title"},{"value":"Neurochemistry International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuint.2017.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}